Clinical Observation on Valsartan Plus Verapamil in the Treatment of Essential Hypertension Complicated with Paroxysmal Atrial Fibrillation/
Abstract：Objective:To study the effects of valsartan combined with verapamil on paroxysmal atrial fibrillation(PAF) in patient with mild to moderate essential hypertension (EH).Methods:Eighty patients of mild to moderate EH with PAF were randomized to valsartan plus verapamil group or valsartan group. All the patients took amlodipine besylate per day orally.The patients in valsartan plus verapamil groups took valsartan 80-160 mg and verapamil 120-480 mg per day orally.The patients in valsartan group took valsartan 80-160 mg per day orally.The inner diameter of left atrium and the onsets of atrial fibrillation (AF) were measured at before and after the therapeutic 3 th,6 th,and 9 th month.Results:The inner diameter of left atrium in two groups were not significantly changed at the 9 th month,the onsets of AF during the 6 th-9 th month were decreased compared with pre-treatment in two groups and decreased significantly in valsartan plus verapamil group.Conclusion:Valsartan can prevent the enlargement of left atrium of patient with EH complicated with PAF,and reduce the onsets of AF, but the effect of valsartan combined with verapamil is more significant to reduce the onsets of AF.
Keywords：Essential HypertensionParoxysmal atrial fibrillationValsartanVerapamil
Publication Date：2013-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)